EpitogenX: embracing disruption through innovative technologies.
EpitogenX is a forward-thinking biotech with innovative platforms backed by a world-leading scientific team. We strive to improve global healthcare outcomes by offering innovative solutions and affordable products.
EpitogenX Ltd is a holding company aiming to build on the successes of its subsidiary, Vertebrate Antibodies Ltd, to transform the biotech industry by providing high-quality services and products for both the medical and veterinary sectors.
Our EpitoGen® and AI EpitoPrediktTM technologies come together to create a powerful game-changing platform that will transform diagnostics, vaccine design, biotherapeutics, and antibody development.
With the support of Innova Medical Group Inc, we also aim to provide accurate, simple, accessible, and affordable point-of-care testing systems.
Using AI models we offer in silico solutions, validated in vitro and applied to create prototype clinical products using EpitoGen® Technology.
Products developed using this technology are compatible with gold standard lab-based and point-of-care applications (i.e. ELISA, LFA, microfluidics), making them affordable and user friendly.
Our Mission
“To improve life by making accurate and affordable products accessible to community-based healthcare and middle/low-income countries”. At EpitogenX we are very proud of the important role we will play in providing our partners with the means to deliver clinical products.
“Our Vision is to make our game-changing EpitoGen® technology available globally to transform the diagnostic sector”
Operational Team
CHIEF TECHNOLOGY OFFICER
Dr Ayham Alnabulsi
CHIEF EXECUTIVE OFFICER
Dr Abdo Alnabulsi
CHIEF SCIENTIFIC OFFICER
Dr Tiehui Wang
IMMUNOLOGIST
Dr Yehfang Hu
LEAD POC SCIENTIST
Alex Wang
SCIENTIFIC WRITER
Dr Donald Falconer
Aquaculture Research Director
Dr Steve Bird
SENIOR SCIENTIST
Dr Megan Simpson
KTP ASSOCIATE - SEROLOGY TEST DEVELOPMENT
Dr Rodanthi Zindrili
Advisory Board
Prof Graeme Murray
Dr Wei Pang
Prof Chris Secombes
BIOTECHNOLOGY OFFICER
Dr Ting-Yu Wang
Prof Mirela Delibegovic
Dr Brittain-Long
Breakthrough Solutions
Serodiagnosis
We offer in silico and in vitro technologies that can accelerate the development of antibody-based assays, improve assay performance, and reduce cost and lead production time. Our novel technology has been created to overcome the main technical issues that have hindered the development of accurate serological tests.
By virtue of the multiplexing capacity of our platform, we can develop break-through diagnostic products. For example, EpitoPrediktTM can isolate allergy associated epitopes, paving the way for the development of effective allergy testing.
Diagnostic Products
EpitoGen® scaffold provides a superior framework to express and display antibody fragments for diagnostic testing. EpitoGen® also increases production yield, improves stability, and reduces cost.
Importantly, the scaffold is engineered to bind preferentially to testing surfaces, ensuring correct orientation of the displayed paratope, consequently improving assay performance.
Vaccine Design
EpitoPrediktTM and EpitoGen® can be used together to accelerate the development of epitope/subunit-based vaccines whilst offering significant safety advantages. EpitoPrediktTM ‘s ability to identify B-cell, CTL and HTL epitopes enhances the efficacy of current vaccine platforms, whilst EpitoGen®‘s multiplexing capacity further improves efficacy and provides an efficient delivery system for vaccine candidates.
Our AI software can also identify immune components that will support mucosal vaccine design (i.e. IgA-rich antigens).
Immunogenicity Profiling
Both platforms (EpitoGen® and EpitoPrediktTM) provide in silico and in vitro screening for potential immunogenic signatures of biological candidates for clinical evaluation.
We can identify immunogenic signatures for the lead candidates to carry forward from preclinical and clinical trials, which improves overall safety and reduces the risk of failure due to immunogenicity issues.
Antibody Bioengineering
Nanobodies can be expressed and displayed on our EpitoGen® scaffolds to improve stability and reduce the cost of production.
Epitope-Based Antibodies
Using our EpitoGen® Scaffolds, multiple immunogen epitopes can be displayed and used to improve the efficiency and quality of antibody development.
Do you have a vaccine, diagnostic, recombinant protein, or antibody project? Are you looking for immunogenicity profiling? Please contact us for details.
Technology
EpitogenX brings together two innovative platforms to create game-changing solutions.
EpitoPrediktTM is an AI software that can accurately identify immunodominant epitopes, a crucial component of diagnostic, prophylactic and immunotherapeutic vaccines.
The software is embedded with machine and deep learning algorithms which generate models that can provide accurate solutions for specific biological designs.
Our core technology is called EpitoGen®; a bioengineered recombinant scaffold that can display single or multiple epitopes/antigens, forming the basis of the diagnostic assay.
Both platforms create a self-learning system whereby data generated experimentally is used to train the AI models and improve their predictive accuracy.
Latest news
Learn more about our current projects, the applications of our technology and the company news.
Next Generation Lyme Diagnostics: Multi-Peptide Approach
Lyme Borreliosis, commonly known as Lyme disease, poses a significant health threat worldwide. The condition stems from infection by the bacterial spe
08 April, 2024
Point-of-care and screening tests for early detection of Type 1 Diabetes
EpitogenX is delighted to announce the launch of an Innovate UK Knowledge Transfer Partnership (KTP) between our subsidiary, Vertebrate Antibodies, an
08 September, 2023
EpitoPredikt® and EpitoGen® combine to develop a diagnostic test for Lyme Disease (LD)
The diagnostic pathway in the UK follows a two-step approach using commonly available antibody screening tests. This process is lengthy, complex, expe
02 March, 2023